Skip to content

NIH Websites Are Changing

NAEC Meeting Minutes - September 25, 2026

National Institutes of Health

National Eye Institute
Minutes of the National Advisory Eye Council
One Hundred Seventy Seventh
September 25, 2026 

The National Advisory Eye Council (NAEC) convened its 177th meeting in person at 9:00 a.m. on Friday, September 25, 2026, in Building 31, Conference Room FG, on the NIH campus in Bethesda, Maryland. Dr. Michael F. Chiang, Director of the National Eye Institute (NEI), presided over the meeting as Chair. This was the first in-person Council meeting in approximately two years. The meeting was open to the public for the morning and early afternoon sessions; a closed session followed for confidential discussions, including conflict-of-interest matters and application reviews.

Council Members Present:

Dr. Michael F. Chiang, Chair
Dr. Maria Grant
Dr. Donald Mutti
Dr. Victor Perez Quinones (joining remotely)

Ad Hoc Members Present:

Dr. Michael Abramoff
Dr. David Calkins
Dr. John Maunsell
Dr. Jennifer Sun
Dr. Michael Twa

NIH Staff Members Present:

(The attendee list will be added soon)

WELCOME AND INTRODUCTIONS

— Dr. Michael F. Chiang, Chair, NAEC, and Director, NEI

Dr. Chiang welcomed Council members, ad hoc members, NEI staff, and members of the public, noting that this was the first in-person Council meeting in roughly two years and expressing enthusiasm at convening in Bethesda. He welcomed several ad hoc members joining the Council for this meeting and asked attendees to introduce themselves around the table, including their affiliation and area of expertise. Introductions included representatives from Vanderbilt University Medical Center, the University of Houston College of Optometry, the University of Iowa/Digital Diagnostics, Opus Genetics, the University of Chicago, and Harvard Medical School/Joslin Diabetes Center, spanning expertise in glaucoma, optic nerve degeneration, data science, myopia control, retinal disease and AI, retinal gene therapy, visual cortical processing, and diabetic retinopathy.

Dr. Chiang noted that the agenda allotted one hour for the Director's Report plus thirty minutes of discussion, and that the two would be blended, with Council members invited to weigh in throughout rather than waiting until the end.

NEI DIRECTOR'S REPORT

— Dr. Michael F. Chiang

Dr. Chiang opened by noting that the report would cover developments over the past year to year and a half, recognizing that some material would be familiar to returning members and new to ad hoc members.

NEI Overview

Dr. Chiang reviewed that NEI was established in 1968 by Congress and President Lyndon Johnson as an NIH institute dedicated to vision research, with a current budget of $896.5 million that has been stable for several years. He noted that surveys consistently rank blindness among the conditions Americans fear most, alongside Alzheimer's disease and cancer, and that NEI-funded research has produced eight Nobel Prize winners, reflecting the eye's accessibility as a site for foundational scientific innovation that often generalizes to other fields of medicine. He also cited an estimated $134 billion annual economic burden of vision loss in the United States.

NIH Unified Mission and Funding Strategy

Dr. Chiang discussed NIH Director Dr. Jay Bhattacharya's unified NIH strategy, published roughly a year earlier, which outlines NIH-wide priorities including AI training, new approach methodologies, and replication/reproducibility. He also summarized the unified NIH funding strategy, under which funding decisions should align with NIH and institute missions, prioritize peer-review merit, integrate a breadth of topics and approaches, consider investigator career stage, and promote broad distribution and geographic balance—moving away from strict paylines toward portfolio-based decision-making that weighs need, opportunity cost, and stewardship of taxpayer investment.

NIH Leadership Transitions

Dr. Chiang reported numerous recent NIH leadership changes: Courtney Aklin as new permanent Director of the National Institute of Nursing Research (NINR); Wendy Weber as new Director of the National Center for Complementary and Integrative Health (NCCIH); Dr. Judy Cho (formerly Mount Sinai) as the new Director of the National Human Genome Research Institute (NHGRI); a new acting Director at the National Institute of Allergy and Infectious Diseases (NIAID); Dr. John Gaitanos as new Director and Dr. Dorothy Fink as new Deputy Director of the National Institute of Child Health and Human Development (NICHD); Dr. Jonathan Burke as new Director of the National Institute of Dental and Craniofacial Research (NIDCR); Peter Embi (formerly Vanderbilt) as new Director of the National Library of Medicine (NLM); and Dr. Ray Jacobson as new permanent Director of the Center for Scientific Review (CSR). Within the Office of the Director, Brad Bauer was named Chief AI Officer within the Division of Program Coordination, Planning, and Strategic Initiatives; Kristen Honey was named Chief Partnerships Officer; Josh Denny, CEO of the All of Us program, is transitioning to a senior role at the University of Chicago, with Stephanie Devaney becoming Acting CEO; a new Office of Research Innovation, Validation, and Application was established, to be led by Warren Casey, focused in part on new approach methodologies (NAMs); and Jay Day was named Director of the Office of Research Services.

NEI Mission and Strategic Plan

Dr. Chiang restated the NEI mission—to eliminate vision loss and improve quality of life through vision research—achieved through four priority areas: driving innovative research, fostering collaborations, recruiting and training the next generation of vision scientists, and public education. He described the current five-year NEI strategic plan, published in 2021 and organized around seven cross-cutting areas (genetics, neuroscience, immunology, regenerative medicine, data science, quality of life, and population health), intersecting with a disease-based extramural portfolio (retina, cornea, lens/cataract, glaucoma, optic neuropathies). He reported that NEI is in the process of developing its next five-year strategic plan, informed by a Request for Information that generated hundreds of comments from individuals, institutions, departments, and professional organizations. He noted that more than 90% of the NEI extramural portfolio remains investigator-initiated, but that funding decisions increasingly consider alignment with the strategic plan, and he encouraged investigators to consult NEI program officers regarding alignment.

Awards

Dr. Chiang congratulated Dr. José-Alain Sahel (University of Pittsburgh) and Botond Roska (University of Basel) on receiving the Champalimaud Vision Award for advances in optogenetic vision restoration, and Dr. Lois Smith and Council member Dr. Maria Grant on receiving the 2026 Ludwig von Sallmann Prize for work on mechanisms underlying retinopathy of prematurity, retinitis pigmentosa, AMD, and diabetic retinopathy.

Driving Innovative Research

Dr. Chiang described the visual system as an ideal platform for methodological innovation given its accessibility, transparency, and paired-organ structure enabling internal controls. He highlighted a retinal prosthetic system (work associated with Dr. Daniel Palanker and Dr. José-Alain Sahel) in which a camera-equipped headset transmits visual information to a wireless subretinal implant via near-infrared projection, enabling some patients with severe retinal disease to read letters and words; the underlying science draws on semiconductor physics, wearable electronics, neural engineering, and visual psychophysics.

Gene Therapy: Dr. Chiang noted that the first FDA-approved gene therapy for an inherited disease in any field of medicine was for Leber congenital amaurosis, and that NEI participates in the $80 million, five-year Bespoke Gene Therapy Consortium (a public-private partnership with FDA, industry, and more than ten NIH institutes) developing gene-therapy platforms and regulatory playbooks for ultra-rare diseases. Of the consortium's funded projects, one of seven vector-biology awards and three of eight overall awards involve eye disease, including work led by Dr. Leah Byrne (University of Pittsburgh) on an open-source vector/dose-selection database for retinal gene therapy.

New Approach Methodologies (NAMs): Dr. Chiang described NAMs as human-based models—organoids, microphysiological systems, stem-cell systems, digital twins, and AI/in-silico approaches—intended to reduce reliance on animal testing. He cited the 2011 publication of early retinal organoids, NEI's participation in the NIH-wide Regenerative Medicine Innovation Project (five of twenty funded projects involved eye disease), and a 2022 NEI 3D Retinal Organoid Challenge. He also highlighted first-in-human work from Dr. Kapil Bharti's group on iPSC-derived RPE transplantation for dry AMD, and work by Dr. Ula Jurkunas (Harvard) on autologous limbal stem cell transplantation for corneal disease.

Imaging, AI, and Oculomics: Dr. Chiang contrasted earlier subjective clinical examination methods with current OCT-based imaging, which enables near-histological visualization of ocular structures and function. He noted that the first FDA-authorized autonomous AI system in any field of medicine—for diabetic eye disease—was developed by ad hoc member Dr. Michael Abramoff. He introduced "oculomics," the use of retinal imaging and AI to predict systemic disease, citing published work suggesting AI could identify Parkinson's disease risk years before clinical diagnosis, and noted growing interest in using retinal imaging to supplement or outperform existing cardiovascular risk calculators. NEI's $14 million, three-year Oculomics initiative funded three groups examining the eye as a biomarker for vascular health (Dr. Amani Fawzi), Alzheimer's/Parkinson's disease (Dr. Vivek Srinivasan), and cerebral small-vessel disease (Dr. Jay Wong).

Multimodal Data Programs: Dr. Chiang described NEI's role co-leading the NIH Common Fund Bridge2AI program ($130 million over four years for Stage 1), including an ophthalmology-led project (Dr. Aaron Lee and Dr. Cecilia Lee) recruiting approximately 4,000 participants with type 2 diabetes and collecting multimodal data (EHR, imaging, genomic, survey, and wearable data) now totaling roughly 22,000 participants and four terabytes of publicly available data. Stage 2, recently approved by the NIH Council of Councils, is estimated at $90 million over five years. He also described PRIMED-AI, a roughly $121 million, five-year Common Fund program co-led by NEI to integrate imaging with other multimodal data, develop diagnostic/predictive AI tools, and support real-world clinical implementation; associated funding opportunities were recently released.

Fostering Collaborations, Data Sharing, and Research Culture

Dr. Chiang discussed a shift from individually driven science toward team science and large- scale data sharing, noting persistent community concerns about the NIH data-sharing policy (in effect roughly three years) given that academic incentives—publication counts, authorship position, h-index, and grant dollars—do not inherently reward data sharing. To address this, NEI led the NIH-wide Data Sharing Index ("S Index") Challenge, a $1 million, 14-institute initiative to develop metrics rewarding useful data sharing; three prizes were awarded (teams led by Bhavesh Patel, Shuhan He, and Griffin Weber) at a recent Bethesda award event featuring a keynote and fireside chat with Dr. Bhattacharya. Dr. Chiang reported that he now chairs a related NIH-wide working group examining additional measurable features of "21st century science" beyond data sharing.

Council members offered perspectives on impact metrics: Dr. David Calkins suggested measuring successful translation of discoveries into new treatments, while acknowledging the long timelines involved; Dr. Abramoff described work on an informal "patient impact index" and noted that the diabetic retinopathy AI system traced back to NEI-funded trials from the 1970s; Dr. Jennifer Sun suggested rewarding the adoption of evidence-based approaches in underserved practice settings; and Dr. Donald Mutti raised the need for long-term outcome surveillance infrastructure, using myopia control as an example of a 20–30 year outcome question. Dr. Calkins also cited an Orbis study of tea-leaf pickers in Nepal in which correcting refractive error increased income, as an example of measuring real-world functional impact. Dr. Calkins further suggested that retrospective, AI-assisted analysis of NEI's funding history could help identify which basic-science investments produced the greatest downstream impact, an idea Dr. Chiang connected to ongoing internal discussions of knowledge-graph approaches. Dr. Chiang then described the NIH Common Fund REPEATS program (an estimated $170 million over five years, approved by the NIH Council of Councils shortly before the meeting and co-led by NEI, the National Institute of Neurological Disorders and Stroke, and the National Institute on Aging), intended to improve rigor, reproducibility, and replicability across the scientific ecosystem, research practices, and workforce through initiatives including sector- partnership and multi-team "triangulation" projects. Dr. Maria Grant raised concerns about gaps in bioinformatics literacy among biological researchers, editors, and reviewers, which can make it difficult to adjudicate conflicting analyses of the same dataset. Dr. Chiang responded that triangulation projects are intended to systematically test how variability in reagents, methods, and analytic approaches affects conclusions. Dr. Calkins noted the value of publishing intermediate data to enable AI-assisted replication checks. Dr. Twa raised the potential for next- generation scientific publications that leverage AI for discoverability and rigor assessment, and described prior engagement between NEI and vision-journal editors (including presentations from the National Library of Medicine). Dr. Sun added that methods-focused papers are often undervalued by high-impact journals and encouraged editors to create more space for this work. Dr. Chiang noted NEI's ongoing relationship with editors of major vision journals and interest in exploring new publication models collaboratively.

Real-World Data Networks and Measurement Challenges

Dr. Chiang described the relative scarcity of large-scale, open-access ophthalmic real-world datasets compared to other fields, and contrasted centralized data networks (e.g., the American Academy of Ophthalmology's IRIS Registry) with federated/distributed networks, which avoid complex data-use agreements but require harmonized data definitions. He described ongoing work with the American Academy of Ophthalmology to develop a common data model for eye care, and a $1 million NEI Federated Vision Research Network Challenge (four winners: Dr. Michael Boland, Dr. Michelle [surname not clear in transcript], Dr. George Trichopoulos, and Dr. Gayathri Srinivasan).

Dr. Chiang then introduced two new challenge competitions questioning the continued reliance on traditional eye charts: the Vision Precision Challenge (up to $1 million, registration deadline January 2027), seeking a next-generation, scalable, accurate measure of visual acuity, and the Vision Function Challenge (a separate $1 million prize pool, registration deadline June 2027), seeking a comprehensive, interpretable assessment integrating multiple dimensions of visual function (e.g., contrast sensitivity, glare, low-light and dynamic vision, patient-reported outcomes). Council members offered socialization strategies: Dr. Twa suggested the challenges were well suited to resident research projects; Dr. Calkins recommended parsing the challenge by age group (pediatric, adult, older adult) given differing testing tolerance; Dr. Abramoff emphasized the value of establishing outcomes as FDA trial endpoints to accelerate real-world adoption; Dr. Sun recommended engaging patient advocacy organizations, including groups that have convened externally led patient-focused drug development meetings; and one participant noted that NEI's previous practice of e-mailing funding opportunity announcements to the community appeared to have lapsed.

Consortia and Workforce Development

Dr. Chiang described an effort, prompted by a glaucoma meeting presentation roughly a year earlier, to address the lack of a standard definition of glaucoma, which complicates research robustness, regulatory review, and generalizability; a working group of approximately 30 national experts (led by Dr. Sophia Wong, Dr. Ben Xu, and Dr. Michele Lim) with five subcommittees is now addressing this gap, with Steven Henle coordinating. He also reviewed progress on cerebral visual impairment (CVI), including a 2024 published working definition, coordinated editorials across ophthalmology, pediatrics, and neurology literature, and ongoing development of a national CVI registry supported by Santa Tumminia and Amberlynn Reed. He briefly noted continued progress of the NEI-supported Ocular Surface Microbiome Consortium (led initially by Lisa Neuhold), which is nearing completion and expected to be highlighted at the 2027 ARVO meeting.

On workforce development, Dr. Chiang described the R38 research-training program (supporting one to two dedicated research years within ophthalmology residency), with initial sites at Johns Hopkins, Stanford, and UCSF and additional programs in development (led by Neeraj Agarwal and Ashley Fortress), and the Council of Vision Editors Fellowship program, which pairs early- career faculty with major vision journals for editorial mentorship—described as a field-wide model not replicated elsewhere in biomedicine.

Dr. Chiang closed his formal remarks with reflections on preparing the vision workforce for AI- enabled practice, raising open questions about the enduring value of human clinicians and scientists in an era of rapidly advancing AI capability, and describing an NIH-wide "I Teach" conference convened at the University of Illinois Chicago (organized with Houmam Araj) bringing together clinicians, educators, AI developers, and accrediting organizations (AMA, ACGME, ABMS) to consider the future of medical education and training.

Council discussion on AI and the future of practice followed: Dr. Abramoff raised the emergence of autonomous cataract robotics and questioned the future division of labor between routine and complex surgical cases; Dr. Calkins emphasized that AI tool development cannot proceed without close engagement from insurers and the FDA regarding acceptable evidentiary and reimbursement standards; Dr. Grant emphasized the growing difficulty of integrating care across subspecialties and the importance of teaching this integration earlier in training; and Dr. Mutti raised human accountability as a distinct value humans provide even as diagnosis and surgery become increasingly automated.

Dr. Chiang closed by noting ongoing work, led in part by Kathryn Demott, to improve public communication of NEI's impact, including a series of short videos (e.g., on gene therapy and Luxturna).

NEI BUDGET UPDATE

— Karen Colbert, NEI Budget Officer

Ms. Colbert reported that NEI's congressional appropriation has remained level at $896.5 million annually since FY2023. She noted that final FY2026 (October 1, 2025–September 30, 2026) spending figures were not yet available but that historical patterns indicate approximately 80% of NEI resources support extramural grants, about 5% support research and development contracts, approximately 4% support research management and support, and roughly 12–13% support the intramural research program; she expects FY2026's profile to be similar.

Ms. Colbert explained that a continuing resolution (CR) signed into law on September 2, 2026, funds the federal government, including NIH and NEI, through December 11, 2026. She clarified that a CR is a temporary funding mechanism that generally continues prior-year funding rates and authorities for the period covered—in this case 72 days, or approximately 19.7% of the fiscal year—and does not represent an upfront allocation of a prorated annual budget. She reviewed possible outcomes as the CR deadline approaches: enactment of full-year appropriations, inclusion of Labor-HHS-Education funding in a larger appropriations package, passage of an additional CR, or a lapse in appropriations resulting in a funding gap or shutdown. She noted that the November 2026 midterm elections fall within the CR window and do not themselves alter current-year funding, though results could affect future congressional priorities during the subsequent lame-duck session.

Ms. Colbert distinguished the FY2027 President's Budget Request—which proposes approximately $833 million for NEI and significant NIH-wide reductions—from an enacted appropriation, emphasizing that Congress retains appropriations authority and that NEI's final FY2027 funding level remains undetermined.

FIRESIDE CHAT WITH THE NIH DIRECTOR

— Dr. Jay Bhattacharya, Director, National Institutes of Health, in conversation with Dr. Michael F. Chiang

Dr. Chiang introduced Dr. Bhattacharya, the 18th Director of NIH, noting this was a new, more conversational format for the Council. Dr. Bhattacharya opened with brief remarks highlighting NEI leadership on several NIH-wide efforts, including PRIMED-AI and REPEATS, and previewed NIH plans to fund nearly 1,600 new early-career investigators with R01 awards in FY2026—one of the highest levels in recent memory—citing his own published research finding that early-career scientists are disproportionately likely to introduce novel ideas into the literature. He described recent intramural NEI accomplishments, including first-in-human retinal tissue replacement, new retinitis pigmentosa biomarkers, and AREDS-related findings that nutritional supplementation reduces progression from intermediate to advanced AMD by approximately 25%.

Dr. Bhattacharya articulated several broader NIH priorities: empowering early-career scientists, investing in frontier ("edge") science rather than only safe, publishable results, democratizing funding opportunities geographically, strengthening replication as a foundation for scientific trust, and shifting success metrics from publication counts toward ultimate health impact. He described the unified funding strategy as a tool allowing institute directors, including Dr. Chiang, to construct portfolios reflecting full peer-review input and strategic priorities rather than a single numerical score, while preserving peer review as the foundation of the system. He noted that cross-institute collaboration under this model is organic and relationship-driven, exemplified by "Highlighted Topics," which allow one or more institutes to rapidly signal scientific priorities without a new formal funding announcement.

Dr. Bhattacharya also discussed: the REPEATS program's community-driven model for identifying which scientific claims merit replication; a new Link Discoveries tool on PubMed that surfaces the semantic neighborhood, citation relationships, and timeline around a given paper to help researchers assess a body of evidence rather than a single publication (noting that two of the tool's initial seed articles came from NEI-supported work by Dr. Emily Chew and Dr. Kapil Bharti); "Highlighted Topics" as a faster mechanism for signaling NIH priorities; and an unresolved policy question regarding the return of individual clinical trial results to research participants, balancing participants' interest in their own health information against the risk of providing results without adequate interpretive context.

On AI, Dr. Bhattacharya distinguished general-purpose language models from data-grounded scientific tools such as AlphaFold, expressing confidence in AI's potential for basic biological discovery (e.g., genome annotation) while cautioning that AI outputs still require experimental validation and are not infallible. He noted that clinical AI deployment requires further research to characterize when tools work, when they fail, and how to manage false positives and negatives, using OCT interpretation as an example relevant to his own glaucoma care.

In discussion, Dr. Calkins raised the tension between team-based science and individual- investigator metrics (e.g., contact PI counts on R01s) used in academic evaluation; Dr. Bhattacharya agreed this reflects a broader need for new scientific productivity metrics and noted that flexible funding mechanisms (e.g., P-awards, multi-PI R01s) already support team science, though culture change will require collective effort across the research community.

OPEN DISCUSSION: TEAM SCIENCE AND ACADEMIC-INDUSTRY PARTNERSHIP

— Panel discussion with Dr. Laura Ensign (Johns Hopkins, Wilmer Eye Institute), Dr. Ash Jayagopal (Opus Genetics), and Kirsten Mukerji (National Science Foundation), moderated by Dr. Michael F. Chiang

Dr. Chiang introduced the afternoon panel as a continuation of the morning's discussion on moving discoveries from publications toward real-world treatments and products, and on fostering collaboration between academia and industry.

Panelist Introductions. Dr. Ensign, Vice Chair for Research and Director of the Center for Nanomedicine at the Wilmer Eye Institute, described the "delivery problem" in pharmaceutical development—most drugs are formulated for systemic administration despite needing to act on specific tissues—and the eye's unique anatomical barriers. She cited lipid nanoparticle-based mRNA vaccines, viral vector gene therapy (e.g., Luxturna), sustained-release implants (e.g., port delivery systems, intracameral implants), and nanomicelle eye drops as examples of nanomedicine improving targeting, reducing side effects, and extending dosing intervals. Dr. Jayagopal described Opus Genetics, founded in 2021 with Dr. Jean Bennett (inventor of Luxturna) to advance retinal gene therapies for inherited retinal diseases, noting the company's seven gene-therapy programs all trace their foundations to NEI-supported investigator-initiated research, including three NEI SBIR awards.

Kirsten Mukerji, representing NSF's Technology, Innovation and Partnership (TIP) Directorate (standing in for Erwin Gianchandani), described TIP's mission to bridge the gap between federally funded R&D and market-ready commercialization (the "Valley of Opportunity"), including the long-standing I-Corps program and the newly launched, larger-scale X Labs initiative, which funds cross-sector platform teams across five technology tracks, including one in "sequence to function" relevant to biology.

Translation Case Studies. Dr. Ensign described an ocular gel-forming eye-drop therapy that progressed from a Wilmer seed grant through an NEI R01, Maryland Innovation Initiative funding, company formation, NEI SBIR support, and IND-enabling studies to a partnership with a large pharmaceutical company and approximately five clinical trials, emphasizing that nearly all intermediate-stage funding was government- and largely NEI-supported. Dr. Jayagopal described Opus's use of NEI-supported patient-derived iPSC lines to model ultra-rare inherited retinal diseases and de-risk therapeutic candidates before costly animal and clinical studies, given the limitations of mouse models for these conditions.

Identified Gaps. Dr. Ensign identified a gap in entrepreneurial training for faculty and trainees regarding intellectual property, patenting, regulatory pathways, and translating "can we do this" into "should we do this" from a commercialization standpoint. Dr. Jayagopal noted that investors increasingly require near-term clinical proof-of-concept before engaging, and that early, well- designed "de-risking" experiments (e.g., organoid, explant, and iPSC-based studies) can shorten translational timelines by many months, which can determine whether a program remains financeable. Ms. Mukerji organized observed gaps into "people" (entrepreneurial training), "process" (speed of federal funding decisions), and "product" (resources needed to scale from prototype to manufacturing).

Dr. Calkins proposed that NEI serve as a more intentional "matchmaking" conduit connecting academic discovery, clinical need, and industry development, rather than relying on informal personal networks, and separately advocated for continued investment in non-human primate research. In response to a question from Dr. Grant about engaging investors and navigating university technology-transfer offices, Dr. Jayagopal recommended that investigators first cultivate interest from industry partners and then bring that external interest to their technology- transfer office to build internal advocacy.

Investment Models for Rare Disease. Dr. Abramoff raised concerns that current venture investment increasingly favors short timelines and very large financial outcomes, poorly suited to therapies requiring eight to ten years of development, and asked whether aggregating multiple rare-disease assets into a single investment package could help. Dr. Jayagopal noted that Opus Genetics was itself founded on this model, aggregating IND-ready, university-originated assets. He and Ms. Mukerji discussed SBIR funding (including phased/"Phase Zero" mechanisms at some agencies) as a tool to bridge the gap between strong preclinical data and IND-ready status, and Dr. Bhattacharya's earlier-referenced Bespoke Gene Therapy Consortium as a model for reusable regulatory playbooks for ultra-rare diseases.

Accelerating Development. Panelists discussed additional levers for shortening translational timelines: fast-tracking federal funding decisions when earlier-phase milestones have already been met (an approach Ms. Mukerji said NSF uses between SBIR Phase I and Phase II); re- examining costly, entrenched manufacturing practices for cell and gene therapies (Dr. Jayagopal described early work using plant-cell-based AAV production via Agrobacterium transformation, which preliminary data suggest may substantially reduce manufacturing costs while maintaining comparable product quality); expanding availability of academic GMP manufacturing facilities through federal construction-grant support; and developing composite or multi-endpoint clinical trial scoring approaches with FDA so that trials showing strong secondary outcomes are not categorically failed for narrowly missing a single primary endpoint.

Research Dissemination. Dr. Chiang raised a broader question about evolving norms for scientific publication, citing a recent discussion with journal editors regarding tension between academic expectations of full data disclosure and industry's need to protect proprietary datasets. Dr. Ensign noted that academic methods sections often omit details needed for independent replication, more often from oversight than intent, and described efforts in her own lab to document methods to a near-regulatory standard given eventual translational goals. Ms. Mukerji noted that NSF has begun supplementing publication counts with patent activity as an evaluation metric, while acknowledging neither fully captures reproducibility or translational readiness, and noted some companies' willingness to publicly dedicate or open-source selected IP depending on partnership terms. Dr. Chiang noted that NEI's ongoing metrics-and-incentives working group is engaging NSF in related listening sessions.

Closing Recommendations. In response to a question from Dr. Chiang about priorities for the upcoming NEI strategic plan, panelists recommended: continued investment in long-term community resources that only NEI can sustain (e.g., natural history studies, genotype-phenotype datasets, patient-derived cell lines, and large-animal models), citing Stargardt disease research as a model; maintaining balanced investment across basic, clinical, and translational science rather than shifting resources away from foundational work; developing more structured mechanisms for connecting complementary investigators, industry partners, and investors; creating a forum for industry to present structured analyses of unmet clinical needs and translational barriers to inform NEI priorities; and pursuing specific NEI-NSF collaboration mechanisms, including co- funded tracks within NSF opportunities (such as the X Labs sequence-to-function track), prize challenges, transitions from NSF SBIR Phase I to NIH follow-on funding, and joint entrepreneurial training.

Dr. Chiang closed the session by announcing that NEI's new translational funding opportunity (R61/R33 mechanism) had been published that day, thanking Tony Gover and Sangeeta Bhargava for their work on the notice.

CLOSING REMARKS

Dr. Chiang thanked Nathan Brown, Bronte Williams Washington, and the broader NEI staff for organizing the meeting, as well as Dr. Laura Ensign, Dr. Ash Jayagopal, and Kirsten Mukerji for their afternoon presentations, and Dr. Bhattacharya for participating in the fireside-chat format. He thanked the Council and ad hoc members for traveling to Bethesda and expressed appreciation for Dr. Victor Perez Quinones's remote participation from Puerto Rico. He noted the next Council meeting would take place in approximately four months. The open session of the 177th meeting of the National Advisory Eye Council was adjourned at 2:30 p.m., followed by a closed session beginning at 2:45 p.m.

CLOSED SESSION

This portion of the meeting was closed to the public in accordance with the determination that this session concerned matters exempt from mandatory disclosure under Sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code, and Section 1009(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. §§ 1001-1014). Members absented themselves from the meeting during discussion of and voting on applications from their own institutions or other applications in which there was a potential conflict of interest, real or apparent. Members were asked to sign a statement to this effect.

REVIEW OF APPLICATIONS

NAEC members reviewed 536 NEI-primary applications requesting $103,339,533 (direct costs, year 01) Another 194 applications where NEI was a secondary institute requesting $126,474,447 (direct costs, year 01). Council concurred with Institutional Review Group recommendations on these 730 applications.

ADJOURNMENT

The 177th meeting of the National Advisory Eye Council was adjourned at 3:30 p.m. on September 25, 2026

CLOSED SESSION ATTENDEES

Council Members Present:

Dr. Michael F. Chiang, Chair
Dr. Anna Han, Executive Secretary
Dr. Maria Grant
Dr. Donald Mutti
Dr. Victor Perez Quinones (virtually)
Ad Hoc Members Present:
Dr. Michael Abramoff
Dr. David Calkins
Dr. John Maunsell
Dr. Jennifer Sun
Dr. Michael Twa

NIH Staff Members Present:

(The attendee list will be added soon)

CERTIFICATION

We hereby certify that, to the best of our knowledge, the foregoing minutes and
attachment(s) are accurate and complete.

______________________________________
Michael F. Chiang, MD
Chair
National Advisory Eye Council

 

______________________________________
Hyo-Jung Han, PhD
Executive Secretary
National Advisory Eye Council

Last updated: November 19, 2026